Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
37 445 EUR
37 445 EUR
23 003 EUR
23 003 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for income tax expense
2 387 EUR
219,000 EUR
Adjustments for decrease (increase) in trade accounts receivable
3 157 EUR
578,000 EUR
Adjustments for increase (decrease) in trade accounts payable
1 574 EUR
759,000 EUR
Adjustments for provisions
- EUR
91,000 EUR
Adjustments for share-based payments
2 088 EUR
1 746 EUR
Income taxes paid (refund), classified as operating activities
- EUR
- EUR
Cash flows from (used in) operating activities
48 440 EUR
19 764 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
46 909 EUR
507,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
1 157 EUR
11 357 EUR
Proceeds from borrowings, classified as financing activities
2 107 EUR
5 023 EUR
Repayments of borrowings, classified as financing activities
5 443 EUR
2 719 EUR
Payments of lease liabilities, classified as financing activities
810,000 EUR
637,000 EUR
Interest paid, classified as financing activities
469,000 EUR
- EUR
Other inflows (outflows) of cash, classified as financing activities
- EUR
Cash flows from (used in) financing activities
3 458 EUR
13 324 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
- EUR
- EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
1 927 EUR
6 948 EUR
Cash and cash equivalents
16 745 EUR
18 672 EUR
25 620 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.